Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Exclusion Criteria

• •1. concurrent use of a corticosteroid equivalent to \>5 mg/day of prednisolone
• •2. applicable an item for the contraindication of filgotinib or tocilizumab
• •3. a previous use of a JAK inhibitor or IL-6 inhibitor
• •4. treatment with a corticosteroid and csDMARD and change of dose within 4 weeks prior to the providing consent
• •5. treatment with a biologic DMARD or a biosimilar DMARD (ie, infliximab, biosimilar of infliximab, adalimumab, biosimilar of adalimumab, golimumab, certolizumab pegol or abatacept) within 8 weeks prior to the providing consent
• •6. treatment with a TNF inhibitor (ie, etanercept or biosimilar of etanercept) within 4 weeks prior to the providing consent
• •7. use of a prohibited drug or therapy, other than the agents noted above, within 4 weeks prior to the providing consent
• •8. a complication causing musculoskeletal disorders other than RA (ie, ankylosing spondyloarthritis, reactive arthritis, psoriatic arthritis, crystal-induced arthritis, systemic lupus erythematosus, systemic scleroderma, inflammatory myopathy, or mixed connective tissue disease)
• •9. current pregnancy, breastfeeding, or noncompliant with a medically approved contraceptive regimen during and 12 months after the study period
• •10. inappropriateness for inclusion in this study as determined by the investigator